BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-1170@pharmaconomics
DTSTAMP:20260707T041128Z
DTSTART;VALUE=DATE:20260327
DTEND;VALUE=DATE:20260328
SUMMARY:GSK PDUFA — linerixibat
DESCRIPTION:The FDA's approval decision on linerixibat for cholestatic pruritus in primary biliary cholangitis (PBC) is due Mar 27\, 2026. A green light opens the market\; a complete response letter (CRL) usually sinks the stock.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1131399/000165495426001580/a4535u.htm\n\nTrack it: https://www.pharmaconomics.com/e/1170
URL:https://www.pharmaconomics.com/e/1170
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:GSK catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR